Business Context and Reporting Period
Company: NRX Pharmaceuticals, Inc. (NRXP)
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2026
Reporting Period: Event-based report regarding a specific development milestone.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Subsidiary Formation: In April 2026, the Company incorporated NRx Defense Systems, Inc. ("NRXD"), a Florida-based R&D subsidiary focused on neuroplastic treatments combining D-cycloserine with Transcranial Magnetic Stimulation (TMS).
- DARPA Proposal Selection: On July 21, 2026, NRXD received notification from the Defense Advanced Research Projects Agency (DARPA) that its proposal for the "Synaptic Plasticity Augmented Rapid Circuit Stimulation" (SPARC-TMS) clinical trial was selected for negotiation of a potential award.
- Regulatory Status: The SPARC-TMS protocol is approved by the FDA as a Phase 2/3 trial (NCT07227103).
Outlook, Risks, and Management Commentary
- Project Scope: The trial aims to demonstrate the efficacy of robotic-enabled TMS combined with NRX-101 (D-cycloserine/lurasidone) for depression remission. NRX-101 holds FDA Breakthrough Therapy Designation.
- Study Locations: Planned sites include Harvard Mclean Hospital, HOPE Therapeutics clinics, and military treatment facilities such as Walter Reed National Military Medical Center.
- Material Risk/Contingency: The selection for negotiation does not constitute a notice of award, a commitment by DARPA, or authorization to incur costs. Any potential award is subject to successful negotiation of definitive terms.
Investor Verification Checklist
- Verify the status of contract negotiations between NRXD and DARPA/DSO.
- Confirm the timeline for the commencement of the SPARC-TMS Phase 2/3 trial.
- Review the specific terms of the potential award, including funding amounts and milestones, once finalized.
- Monitor FDA communications regarding the ongoing Phase 2/3 trial (NCT07227103).